This company has been marked as potentially delisted and may not be actively trading. Novus Therapeutics (NVUS) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock NVUS vs. CING, CMMB, ALLR, UBX, LPCN, SLGL, EDSA, EQ, LPTX, and BFRGShould you be buying Novus Therapeutics stock or one of its competitors? The main competitors of Novus Therapeutics include Cingulate (CING), Chemomab Therapeutics (CMMB), Allarity Therapeutics (ALLR), Unity Biotechnology (UBX), Lipocine (LPCN), Sol-Gel Technologies (SLGL), Edesa Biotech (EDSA), Equillium (EQ), Leap Therapeutics (LPTX), and Bullfrog AI (BFRG). These companies are all part of the "medical" sector. Novus Therapeutics vs. Cingulate Chemomab Therapeutics Allarity Therapeutics Unity Biotechnology Lipocine Sol-Gel Technologies Edesa Biotech Equillium Leap Therapeutics Bullfrog AI Novus Therapeutics (NASDAQ:NVUS) and Cingulate (NASDAQ:CING) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, community ranking, media sentiment and analyst recommendations. Does the MarketBeat Community prefer NVUS or CING? Novus Therapeutics received 240 more outperform votes than Cingulate when rated by MarketBeat users. However, 80.00% of users gave Cingulate an outperform vote while only 66.84% of users gave Novus Therapeutics an outperform vote. CompanyUnderperformOutperformNovus TherapeuticsOutperform Votes25266.84% Underperform Votes12533.16% CingulateOutperform Votes1280.00% Underperform Votes320.00% Do insiders and institutionals have more ownership in NVUS or CING? 41.3% of Cingulate shares are owned by institutional investors. 2.2% of Novus Therapeutics shares are owned by company insiders. Comparatively, 17.1% of Cingulate shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media favor NVUS or CING? In the previous week, Cingulate had 3 more articles in the media than Novus Therapeutics. MarketBeat recorded 3 mentions for Cingulate and 0 mentions for Novus Therapeutics. Cingulate's average media sentiment score of 0.13 beat Novus Therapeutics' score of 0.00 indicating that Cingulate is being referred to more favorably in the news media. Company Overall Sentiment Novus Therapeutics Neutral Cingulate Neutral Which has preferable earnings & valuation, NVUS or CING? Cingulate is trading at a lower price-to-earnings ratio than Novus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNovus TherapeuticsN/AN/A-$16.01M-$21.58-0.15CingulateN/AN/A-$23.53M-$14.64-0.29 Do analysts recommend NVUS or CING? Cingulate has a consensus target price of $30.67, suggesting a potential upside of 613.18%. Given Cingulate's stronger consensus rating and higher possible upside, analysts clearly believe Cingulate is more favorable than Novus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Novus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Cingulate 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Is NVUS or CING more profitable? Novus Therapeutics' return on equity of -133.49% beat Cingulate's return on equity.Company Net Margins Return on Equity Return on Assets Novus TherapeuticsN/A -133.49% -30.52% Cingulate N/A -570.20%-236.15% Which has more risk and volatility, NVUS or CING? Novus Therapeutics has a beta of 2.07, indicating that its stock price is 107% more volatile than the S&P 500. Comparatively, Cingulate has a beta of -0.87, indicating that its stock price is 187% less volatile than the S&P 500. SummaryCingulate beats Novus Therapeutics on 10 of the 16 factors compared between the two stocks. Get Novus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NVUS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NVUS vs. The Competition Export to ExcelMetricNovus TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.65M$6.68B$5.44B$7.80BDividend YieldN/A3.17%5.43%4.30%P/E Ratio-0.147.1422.1418.40Price / SalesN/A238.89389.70101.29Price / CashN/A65.6738.2034.62Price / Book0.256.266.664.18Net Income-$16.01M$142.48M$3.21B$247.71M Novus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NVUSNovus TherapeuticsN/A$3.24-3.6%N/A+70.6%$4.65MN/A-0.147CINGCingulate2.144 of 5 stars$4.29+5.4%$30.67+614.8%+396.9%$16.91MN/A-0.2920Negative NewsGap UpCMMBChemomab Therapeutics3.3686 of 5 stars$1.18+1.3%$9.00+666.0%+98.8%$16.87MN/A-1.1820ALLRAllarity Therapeutics0.4221 of 5 stars$0.99-4.4%N/A-97.4%$16.73MN/A0.0010News CoveragePositive NewsGap UpUBXUnity Biotechnology4.0396 of 5 stars$0.99+4.9%$5.33+440.9%-34.0%$16.62M$240,000.00-0.7560Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageLPCNLipocine2.5018 of 5 stars$3.02+0.4%$10.00+231.0%-29.4%$16.51M$11.20M-4.0610Analyst ForecastGap UpSLGLSol-Gel Technologies2.7431 of 5 stars$0.59+0.5%$5.00+750.3%-12.1%$16.38M$11.71M-1.7350Positive NewsEDSAEdesa Biotech3.116 of 5 stars$2.32-2.7%$21.00+807.1%-46.6%$16.29MN/A-1.2520News CoverageEQEquillium2.9493 of 5 stars$0.44-2.5%$3.00+575.7%-75.8%$16.07M$41.10M-3.2140News CoveragePositive NewsLPTXLeap Therapeutics1.8748 of 5 stars$0.37+3.4%$4.92+1,221.7%-87.4%$15.35MN/A-0.1940BFRGBullfrog AI0.6442 of 5 stars$1.62-2.4%N/A-35.3%$15.25M$60,000.00-1.914 Related Companies and Tools Related Companies CING Alternatives CMMB Alternatives ALLR Alternatives UBX Alternatives LPCN Alternatives SLGL Alternatives EDSA Alternatives EQ Alternatives LPTX Alternatives BFRG Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NVUS) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredIt’s absolute chaos in Silicon Valley right now…If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Novus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NVUS Stock Free NVUS Stock Alerts